Nat Cell Biol:卵巢干细胞标志物有助早期预测卵巢癌

2014-08-11 佚名 生物谷

A*STAR医学生物学研究所(IMB)和生物信息学研究所(BII)科学家发现新的线索,有助及早发现和个性化治疗卵巢癌,卵巢癌的早期诊断是目前最困难的癌症之一,这是由于缺乏疾病所特有的症状。 有三种主要癌症:乳腺癌,卵巢癌和子宫癌,影响女性。其中,卵巢癌是公众最关心的问题,因为由于缺乏明确的预警症状,通常确诊时已是晚期。成功的治疗是困难的,这就导致了高死亡率。 近来,IMB科学家已经成功地鉴定

A*STAR医学生物学研究所(IMB)和生物信息学研究所(BII)科学家发现新的线索,有助及早发现和个性化治疗卵巢癌,卵巢癌的早期诊断是目前最困难的癌症之一,这是由于缺乏疾病所特有的症状。

有三种主要癌症:乳腺癌,卵巢癌和子宫癌,影响女性。其中,卵巢癌是公众最关心的问题,因为由于缺乏明确的预警症状,通常确诊时已是晚期。成功的治疗是困难的,这就导致了高死亡率。

近来,IMB科学家已经成功地鉴定出卵巢干细胞的生物标志物,其可以帮助早期检测卵巢癌,从而允许在疾病的早期阶段开展治疗。

该团队已经确定了分子Lgr5是卵巢表面上皮的一个细胞子集(上皮干细胞)的标志物。Lgr5先前已用于鉴定其它组织包括肠,胃中的干细胞,但是这是第一次,科学家们已经成功地在卵巢中发现这一重要的生物标志物。研究发现,卵巢中的一类上皮干细胞能生成Lgr5和控制卵巢发育

使用卵巢干细胞的标志物Lgr5,卵巢癌可能可以更早地检测到,从而便于在疾病的早期阶段进行更有效的治疗。这些研究结果在线发表在Nature Cell Biology杂志上。

原始出处:

Ng A1, Tan S1, Singh G1, Rizk P1, Swathi Y1, Tan TZ2, Huang RY3, Leushacke M1, Barker N4.Lgr5 marks stem/progenitor cells in ovary and tubal epithelia.Nat Cell Biol. 2014 Aug;16(8):745-57. doi: 10.1038/ncb3000. Epub 2014 Jul 6.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1766886, encodeId=e74f1e6688673, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Jul 15 22:17:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868878, encodeId=1a4418688e862, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Nov 06 17:17:00 CST 2014, time=2014-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840819, encodeId=ef7f184081970, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Aug 24 14:17:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880221, encodeId=e634188022165, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Oct 14 00:17:00 CST 2014, time=2014-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959123, encodeId=784e1959123bd, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 10 20:17:00 CST 2015, time=2015-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917059, encodeId=b025191e05970, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jul 20 19:17:00 CST 2015, time=2015-07-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1766886, encodeId=e74f1e6688673, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Jul 15 22:17:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868878, encodeId=1a4418688e862, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Nov 06 17:17:00 CST 2014, time=2014-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840819, encodeId=ef7f184081970, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Aug 24 14:17:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880221, encodeId=e634188022165, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Oct 14 00:17:00 CST 2014, time=2014-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959123, encodeId=784e1959123bd, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 10 20:17:00 CST 2015, time=2015-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917059, encodeId=b025191e05970, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jul 20 19:17:00 CST 2015, time=2015-07-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1766886, encodeId=e74f1e6688673, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Jul 15 22:17:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868878, encodeId=1a4418688e862, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Nov 06 17:17:00 CST 2014, time=2014-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840819, encodeId=ef7f184081970, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Aug 24 14:17:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880221, encodeId=e634188022165, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Oct 14 00:17:00 CST 2014, time=2014-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959123, encodeId=784e1959123bd, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 10 20:17:00 CST 2015, time=2015-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917059, encodeId=b025191e05970, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jul 20 19:17:00 CST 2015, time=2015-07-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1766886, encodeId=e74f1e6688673, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Jul 15 22:17:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868878, encodeId=1a4418688e862, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Nov 06 17:17:00 CST 2014, time=2014-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840819, encodeId=ef7f184081970, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Aug 24 14:17:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880221, encodeId=e634188022165, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Oct 14 00:17:00 CST 2014, time=2014-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959123, encodeId=784e1959123bd, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 10 20:17:00 CST 2015, time=2015-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917059, encodeId=b025191e05970, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jul 20 19:17:00 CST 2015, time=2015-07-20, status=1, ipAttribution=)]
    2014-10-14 liye789132251
  5. [GetPortalCommentsPageByObjectIdResponse(id=1766886, encodeId=e74f1e6688673, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Jul 15 22:17:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868878, encodeId=1a4418688e862, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Nov 06 17:17:00 CST 2014, time=2014-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840819, encodeId=ef7f184081970, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Aug 24 14:17:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880221, encodeId=e634188022165, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Oct 14 00:17:00 CST 2014, time=2014-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959123, encodeId=784e1959123bd, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 10 20:17:00 CST 2015, time=2015-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917059, encodeId=b025191e05970, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jul 20 19:17:00 CST 2015, time=2015-07-20, status=1, ipAttribution=)]
    2015-07-10 维他命
  6. [GetPortalCommentsPageByObjectIdResponse(id=1766886, encodeId=e74f1e6688673, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Jul 15 22:17:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868878, encodeId=1a4418688e862, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Nov 06 17:17:00 CST 2014, time=2014-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840819, encodeId=ef7f184081970, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Aug 24 14:17:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880221, encodeId=e634188022165, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Oct 14 00:17:00 CST 2014, time=2014-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959123, encodeId=784e1959123bd, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 10 20:17:00 CST 2015, time=2015-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917059, encodeId=b025191e05970, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jul 20 19:17:00 CST 2015, time=2015-07-20, status=1, ipAttribution=)]
    2015-07-20 sunylz

相关资讯

ASCO 2014:进展期卵巢癌:新辅助化疗创伤低于标准治疗

标题:日本妇科肿瘤学组报告:比较在Ⅲ/Ⅳ期卵巢癌">卵巢癌、输卵管癌及原发腹膜癌中首次肿瘤细胞减灭术及新辅助化疗后中间性肿瘤细胞减灭术两组间治疗创伤的Ⅲ期临床随机试验 背景:该课题组在前期治疗Ⅲ/Ⅳ期卵巢、输卵管癌和原发腹膜癌的临床试验中(JCOG 0602)已对比了首次肿瘤细胞减灭术组(PDS)和新辅助化疗后行肿瘤细胞减灭术组(NAC)的治疗结果(EORTC55971 及CHORUS两项

Oncotarget:预测卵巢癌患者新辅助化疗响应的MicroRNA

近日,Oncotarget杂志上的一项新研究发现MicroRNA中的miR-193a-5p表达,与HGF和c-Met蛋白表达一起与卵巢癌患者对新辅助化疗(NACT)的响应有相关性。 主要研究人员Marisa Mariani博士和他的同事试图确定卵巢癌患者抵抗NACT的机制。对一组85例患者的MicroRNA表达进行筛选,计算microRNA和各类基因之间显著相关性。在验证组的109例患者中,定

Ann Intern Med:美国医师学会不推荐常规进行盆腔妇科检查,包括双合诊!

盆腔检查即妇科检查,是妇产科医师最常使用的体格检查方法。检查范围包括外阴、阴道、宫颈、宫体和双侧附件。其中双合诊是盆腔检查中最为重要的项目。然而就在今天,美国医师学会(American College of Physicians,ACP)在《内科学年鉴》发布了一份临床指南,强烈反对为无症状、非妊娠、低风险的成年女性进行常规盆腔检查。这份指南发表后引起了极大反响,包括美国妇产科医师学会(ACOG)在

ASCO 2014:AZ卵巢癌复方药物在2期试验中使PFS延长一倍

一款由阿斯利康奥拉帕尼和西地尼布组成的复方药物在2期临床试验中与奥拉帕尼单独用药相比,使卵巢癌患者的无进展生存期(PFS) 几乎增加一倍。这一初步结果如果在进一步的临床试验中得到正是,它可能会成为铂类化疗药物的替代选择。 这项临床试验由美国国家癌症研究所的研究人员开展,试验受试者为90名对铂类基础治疗药物有初步响应或其肿瘤表达有BRCA基因突变的复发性卵巢癌患者。试验结果在美国临床肿瘤协会会议上得

ASCO 2014:PC与CPT-P方案一线治疗进展期卵巢透明细胞癌疗效相当

标题:日本妇科肿瘤学组(JGOG)报告了随机对照比较紫杉醇联合卡铂(TC)与伊立替康联合顺铂(CPT-P)作为卵巢透明细胞癌(CCC)一线化疗方案的Ⅲ 期临床试验 背景:卵巢透明细胞癌卵作为卵巢上皮性癌的一个组织学亚型,具有不同的临床特征和生物学特性,其发病率在西方仅占卵巢癌">卵巢癌的5%,而在日本高达20%以上。在日本前期的回顾性研究中,发现CCC较卵巢浆液性及内膜样腺癌的化疗敏感性低

ASCO 2014:吴小华谈复发卵巢癌联合靶向治疗试验

大会报告之一复发卵巢癌PARP抑制剂olaparib±抗血管TKI cediranib疗效的对比 题目:一项在复发铂类敏感卵巢癌中对比PARP抑制剂olaparib单药与联合抗血管生成cediranib疗效的2期随机试验(A randomized phase 2 trial comparing efficacy of the combination of the PARP inhi